Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 132

1.

Managing the risks of prostate disease during testosterone replacement therapy in older men: recommendations for a standardized monitoring plan.

Bhasin S, Singh AB, Mac RP, Carter B, Lee MI, Cunningham GR.

J Androl. 2003 May-Jun;24(3):299-311. Review. No abstract available.

2.

Risks of testosterone-replacement therapy and recommendations for monitoring.

Rhoden EL, Morgentaler A.

N Engl J Med. 2004 Jan 29;350(5):482-92. Review. No abstract available.

PMID:
14749457
3.

Testosterone replacement therapy and the risk of prostate cancer. Is there a link?

Barqawi A, Crawford ED.

Int J Impot Res. 2006 Jul-Aug;18(4):323-8. Epub 2005 Nov 10. Review.

PMID:
16281043
4.

Testosterone replacement therapy and prostate cancer: a word of caution.

Brand TC, Canby-Hagino E, Thompson IM.

Curr Urol Rep. 2007 May;8(3):185-9. Review.

PMID:
17459266
6.

Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.

Coward RM, Simhan J, Carson CC 3rd.

BJU Int. 2009 May;103(9):1179-83. doi: 10.1111/j.1464-410X.2008.08240.x. Epub 2008 Dec 23.

7.

[Testosterone and the prostate].

Sperling H, Rossi R, Lümmen G, Rübben H.

Urologe A. 2004 Sep;43(9):1092-6. Review. German.

PMID:
15368045
8.

Testosterone replacement therapy in hypogonadal men and prostate cancer risk.

Kirby R, Gould D.

BJU Int. 2005 Sep;96(4):471-2. No abstract available.

10.

Influence of demographic factors and biochemical characteristics on the prostate-specific antigen (PSA) response to testosterone replacement therapy.

Verit A.

Int J Impot Res. 2006 Nov-Dec;18(6):574; author reply 575. Epub 2006 Aug 24. No abstract available.

PMID:
17075587
11.

Testosterone and ageing: what have we learned since the Institute of Medicine report and what lies ahead?

Miner MM, Seftel AD.

Int J Clin Pract. 2007 Apr;61(4):622-32. Epub 2007 Mar 2. Review.

PMID:
17343664
12.

[Testosterone replacement therapy and prostate cancer. The current position 67 years after the Huggins myth].

Rinnab L, Gust K, Hautmann RE, Küfer R.

Urologe A. 2009 May;48(5):516-22. doi: 10.1007/s00120-009-1954-z. Review. German.

PMID:
19296069
13.

Testosterone and prostate cancer: what are the risks for middle-aged men?

Morgentaler A.

Urol Clin North Am. 2011 May;38(2):119-24. doi: 10.1016/j.ucl.2011.02.002. Epub 2011 Apr 13. Review.

PMID:
21621078
14.

Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials.

Calof OM, Singh AB, Lee ML, Kenny AM, Urban RJ, Tenover JL, Bhasin S.

J Gerontol A Biol Sci Med Sci. 2005 Nov;60(11):1451-7.

PMID:
16339333
15.

[Testosterone substitution with special regard to prostate cancer].

Beintker M, Behre H.

Urologe A. 2008 Dec;47(12):1588-91. doi: 10.1007/s00120-008-1798-y. German.

PMID:
18931991
16.
17.

The role of testosterone replacement therapy following radical prostatectomy.

Khera M, Lipshultz LI.

Urol Clin North Am. 2007 Nov;34(4):549-53, vi. Review.

PMID:
17983894
18.

Testosterone replacement therapy and prostate risks: where's the beef?

Morgentaler A.

Can J Urol. 2006 Feb;13 Suppl 1:40-3. Review.

PMID:
16526980
20.

Risks and benefits of hormone replacement therapy in older men.

Pasqualotto FF, Lucon AM, Hallak J, Pasqualotto EB, Arap S.

Rev Hosp Clin Fac Med Sao Paulo. 2004 Jan;59(1):32-8. Epub 2004 Mar 15. Review.

Supplemental Content

Support Center